Buchumschlag

Altered Glycosylation of PSA in Prostate Cancer Tissue

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Hannu Koistinen, Ruusu‐Maaria Merivirta, Timo‐Pekka Lehto, Anna Lempiäinen, Andrew Erickson, Ulf‐Håkan Stenman, Antti Rannikko, Tuomas Mirtti
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	The Prostate
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Serum Levels of Prostate Specific Antigen, Free PSA, [‐2]proPSA, fPSA/tPSA Ratio, Prostate Health Index, and Glycosylation Patterns of Free PSA in Patients With Benign Prostatic Hyperplasia Pharmacotherapy: Limitations and Future Directions
von: Yitong Weng, et al.
Veröffentlicht: (2025)

pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post‐Initiation of Androgen Deprivation Therapy
von: Piotr Bialas, et al.
Veröffentlicht: (2024)

Beyond Baseline: Serial PSA Measurements and Risk Stratification for Prostate Cancer
von: Anwar E. Ahmed, et al.
Veröffentlicht: (2025)

Comprehensive Analysis of Fraction of Genome Altered in Prostate Cancer Treatment
von: Muhammad Umair, et al.
Veröffentlicht: (2026)

USPSTF Recommendation Against PSA Screening vs. Stage and Cancer‐Specific Mortality in Localized Prostate Cancer
von: Fabian Falkenbach, et al.
Veröffentlicht: (2025)

A Multimarker Model for Prostate Cancer Risk Assessment: Improving Diagnostic Accuracy Beyond PSA
von: Penglu Yang, et al.
Veröffentlicht: (2025)

Serum levels of prostate specific antigen, free PSA, [−2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy
von: Michal Jirásko, et al.
Veröffentlicht: (2024)

Prostate Volume and PSA‐Density Estimation by Transabdominal Ultrasound: Prospective Evidence of Comparative Accuracy to MRI and Transrectal Ultrasound in Prostate Cancer Early Diagnostics
von: Liza M. Kurucz, et al.
Veröffentlicht: (2025)

Association of Weight Loss and BMI on PSA Levels and Overall Survival in Veterans With Metastatic Castrate‐Resistant Prostate Cancer
von: Nicholas Fedele, et al.
Veröffentlicht: (2025)

Smoking Behavior Is Associated With an Altered Immune Landscape in Prostate Cancer: Implications for Patient Outcomes
von: Amod Sharma, et al.
Veröffentlicht: (2026)

Utility of the PROSTest, a Novel Blood‐Based Molecular Assay, Versus PSA for Prostate Cancer Stratification and Detection of Disease
von: Mark Kidd, et al.
Veröffentlicht: (2025)

The Effects of the Blood‐Based S2,3PSA% Test on Prostate Cancer Screening: A Novel Approach to Reduce the Need for MRI and Unnecessary Biopsies
von: Hikari Miura, et al.
Veröffentlicht: (2025)

Altered Ten Eleven Translocation Methylcytosine Dioxygenase Expression and DNA Hydroxymethylation in a Mouse Model of Prostate Cancer
von: Matthew Aguilera, et al.
Veröffentlicht: (2025)

The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy
von: Takeshi Tsutsumi, et al.
Veröffentlicht: (2026)

Diagnostic Performance of the Novel Biomarker S2,3PSA Density for Prostate Biopsy Optimization in Prostate Imaging Reporting and Data System 3–5 Lesions
von: Takanori Tokunaga, et al.
Veröffentlicht: (2025)

Clinicopathological Significance of Extranodal Adipose Tissue Invasion in Metastatic Lymph Nodes in Patients With Prostate Cancer
von: Hirotaka Nagasaka, et al.
Veröffentlicht: (2024)

Predictive Value of PSA Bounce Phenomenon after Stereotactic Body Radiation Therapy in a Large Population of Prostate Cancer Patients Treated By 1.5 T MR Guided Adaptive Technique
von: Andrea Romei, et al.
Veröffentlicht: (2025)

Prostate Specific Antigen Density and Clinically‐Significant Prostate Cancer: The Influence of Prostatic Volume
von: Elizabeth Robinson, et al.
Veröffentlicht: (2025)

Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real‐world setting of metastatic hormone‐sensitive prostate cancer patients
von: Mike Wenzel, et al.
Veröffentlicht: (2024)

Downregulation of NONO Suppresses Proliferation, Migration, and Invasion in Metastatic Prostate Cancer
von: Anna‐Lena Lemster, et al.
Veröffentlicht: (2025)

Prostatic Surgery With Preservation of the Supramonticular Tissue Versus Standard Surgery for Benign Prostatic Hyperplasia: A Systematic Review
von: Giuston Mendoza‐Chuctaya, et al.
Veröffentlicht: (2025)

Assessment of Circulating Neuroendocrine Tumor Markers at Prostate Cancer Diagnosis: An Investigation of Prostate Cancer With Neuroendocrine Features
von: Tatsuya Shimomura, et al.
Veröffentlicht: (2026)

Evidence and Rationale for Prostate Cancer Screening
von: Takeshi Takahashi
Veröffentlicht: (2025)

Castration Resistance Accelerates Prostate Cancer Kinetics
von: Sheila Jonnatan, et al.
Veröffentlicht: (2026)

CHARGE: The “Big Questions” in Prostate Cancer for 2024
von: Andrea K. Miyahira, et al.
Veröffentlicht: (2024)

The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate
von: Yifu Shi, et al.
Veröffentlicht: (2025)

Developments in Ultrasound‐Based Imaging for Prostate Cancer Detection
von: Reid Vassallo, et al.
Veröffentlicht: (2025)

Factors Associated With Male Breast Cancer Incidence Among Prostate Cancer Survivors: Real World Evidence From Veterans Affairs National Prostate Cancer Data Core
von: Erum Z. Whyne, et al.
Veröffentlicht: (2025)

Impact of Holmium Laser Enucleation of the Prostate on Active Surveillance for Prostate Cancer in Patients With Lower Urinary Tract Symptoms
von: Charly Bâcle, et al.
Veröffentlicht: (2025)

The Diagnostic Value of Plasma Small Extracellular Vesicle‐Derived CAIX Protein in Prostate Cancer and Clinically Significant Prostate Cancer: A Study on Predictive Models
von: Haotian Chen, et al.
Veröffentlicht: (2025)

Confirmation of BIK and SAMHD1 as Prostate Cancer Susceptibility Genes
von: Christian P. Pavlovich, et al.
Veröffentlicht: (2025)

Spatial Robustness of Prostate Cancer Biomarkers Evaluated by Spatial Transcriptomics
von: Kristofer G. Taylor, et al.
Veröffentlicht: (2026)

Prostate‐Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone‐Sensitive Prostate Cancer Treated With Apalutamide
von: Christian Andrés Martínez Osorio, et al.
Veröffentlicht: (2025)

Prostate Extracellular Vesicles and Prognostic Biomarkers of Clinically Significant Prostate Cancer: A Prospective Single‐Institution Pilot Study
von: Cameron J. Britton, et al.
Veröffentlicht: (2025)

The Role of Secondary Lesion Biopsy in Detecting Clinically Significant Prostate Cancer
von: Trevor C. Hunt, et al.
Veröffentlicht: (2025)

The 30th Annual Prostate Cancer Foundation Scientific Retreat Report
von: Andrea K. Miyahira, et al.
Veröffentlicht: (2024)

Diagnostic and Prognostic Value of cfDNA Concentration and Fragmentation in Prostate Cancer
von: Marta Victoria Lorenzo‐Sánchez, et al.
Veröffentlicht: (2025)

Androgen Deprivation Therapy: Mitochondrial Dysfunction and Metabolic Impacts in Prostate Cancer
von: Yu‐Hsiang Lin, et al.
Veröffentlicht: (2025)

Enhancing Prostate Cancer Diagnosis: The Combined Value of PHI and mpMRI
von: Y. M. Yáñez‐Castillo, et al.
Veröffentlicht: (2025)

Size and SUVmax define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer
von: Fabian Falkenbach, et al.
Veröffentlicht: (2024)